Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives

Obstetrics and Gynecology

Volumn 110, Issue 3, 2007, Pages 587-593

  Seeger, John D ^a   Loughlin, Jeanne ^b   Eng, P Mona ^b   Clifford, C Robin ^b   Cutone, Jennifer ^b   Walker, Alexander M ^b  

^a i3 Drug Safety   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DROSPIRENONE PLUS ETHINYLESTRADIOL; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH CARE; HEALTH INSURANCE; HUMAN; MEDICAL RECORD; MEDICAL SERVICE; NORMAL HUMAN; ORAL CONTRACEPTION; POISSON DISTRIBUTION; PRESCRIPTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK FACTOR; SCHOOL CHILD; THROMBOEMBOLISM; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; HEART ARRHYTHMIA; HEART INFARCTION; HYPERTENSION; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL HISTORY;

ADOLESCENT; ADULT; ANDROSTENES; CHILD; COHORT STUDIES; CONTRACEPTIVES, ORAL, COMBINED; ETHINYL ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM;

EID: 34548437530     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000279448.62221.a8     Document Type: Article

References (17)

1. Heinemann LA, Dinger J. Safety of a new oral contraceptive containing drospirenone. Drug Saf 2004;27:1001-18.
2. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62:29-38.
3. van Grootheest K, Vrieling T. Thromboembolism associated with the new contraceptive Yasmin. BMJ 2003;326:257.
4. Pearce HM, Layton D, Wilton LV, Shakir S. Deep vein thrombosis and pulmonary embolism reported in the Prescription Event Monitoring Study of Yasmin. Br J Clin Pharmacol 2005;60:98-102.
5. Sheldon T. Dutch GPs warned against new contraceptive pill. BMJ 2002;324:869.
6. Blann AD, Lip GY. Venous thromboembolism. BMJ 2006;332:215-9.
7. U.S. Food and Drug Administration. Postmarketing study commitments. Available at: http://www.fda.gov/cder/pmc/default.htm. Retrieved June 29, 2007.
8. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
9. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol 1999;150:327-33.
10. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
11. Rubin DB, Thomas N. Matching using estimated propensity scores: relating theory to practice. Biometrics 1996;52:249-64.
12. Seeger JD, Williams PL, Walker AM. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf 2005;14:465-76.
13. Rothman KJ, Greenland S, editors. Modern epidemiology. 2nd ed. Philadelphia (PA): Lippincott-Raven; 1998.
14. Daly L. Simple SAS macros for the calculation of exact binomial and Poisson confidence limits. Comput Biol Med 1992;22:351-61.
15. Klipping C, Marr J. Effects of two combined oral contraceptives containing ethinyl estradiol 20 μg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism. Contraception 2005;71:409-16.
16. Kluft C, Endrikat J, Mulder SM, Gerlinger C, Heithecker R. A prospective study on the effects on hemostasis of two oral contraceptives containing drospirenone in combination with either 30 or 20 microg ethinyl estradiol and a reference containing desogestrel and 30 microg ethinyl estradiol. Contraception 2006;73:336-43.
17. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18:797-804.